The DOI matches its Crossref record; 79 of the 79 references it cites were found in a registry or an index.
Cancer statistics, 2026
Open accessAbstract
Each year, the American Cancer Society estimates the numbers of new cancer cases and deaths in the United States and compiles the most recent data on population‐based cancer occurrence and outcomes using data collected by central cancer registries (incidence, through 2022) and the National Center for Health Statistics (mortality, through 2023). In 2026, approximately 2,114,850 new cancer cases and 626,140 cancer deaths are projected to occur in the United States. The cancer mortality rate continued to decline through 2023, averting 4.8 million deaths since 1991, largely because of smoking reductions, earlier detection, and improved treatment. These interventions are also evident in rising 5‐year relative survival, which reached a milestone 70% for diagnoses during 2015–2021 overall, 69% for regional‐stage disease, and 35% for distant‐stage (metastatic) disease, up from 63%, 54%, and 17%, respectively, in the mid‐1990s. People with high‐mortality cancers and advanced diagnoses had the largest gains, including increases from 32% to 62% for myeloma, 7% to 22% for liver cancer, 16% to 35% for metastatic melanoma, 8% to 18% for metastatic rectal cancer, 20% to 37% for regional lung cancer, and 2% to 10% for metastatic lung cancer. Nevertheless, lung cancer will cause more deaths in 2026 than second‐ranking colorectal cancer and third‐ranking pancreatic cancer combined. In summary, decades of scientific investment have translated to longer lives for people with even the most fatal cancers. However, continued progress is threatened by proposed federal cuts to cancer research and health insurance, which provides access to life‐saving cancer treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma
Finn, R. S., Qin, S., Ikeda, M., Galle, P. R., Ducreux, M., Kim, T.-Y., Kudo, M., Breder, V., Merle, P., Kaseb, A. O., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1915745 · Cited by 7,470
Human Papillomavirus and Survival of Patients with Oropharyngeal Cancer
Ang, K. K., Harris, J., Wheeler, R., Weber, R., Rosenthal, D. I., Nguyen-Tân, P. F., Westra, W. H., Chung, C. H., Jordan, R. C., Lu, C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0912217 · Cited by 6,566
Sex differences in immune responses
Klein, S. L., & Flanagan, K. L. (2016) · Nature Reviews Immunology · doi:10.1038/nri.2016.90 · Cited by 6,370
Structural racism and health inequities in the USA: evidence and interventions
Bailey, Z. D., Krieger, N., Agénor, M., Graves, J., Linos, N., & Bassett, M. T. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30569-x · Cited by 5,203
Reduced Lung-Cancer Mortality with Volume CT Screening in a Randomized Trial
de Koning, H. J., van der Aalst, C. M., de Jong, P. A., Scholten, E. T., Nackaerts, K., Heuvelmans, M. A., Lammers, J.-W. J., Weenink, C., Yousaf-Khan, U., Horeweg, N., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1911793 · Cited by 3,624
Dasari, A., Shen, C., Halperin, D., Zhao, B., Zhou, S., Xu, Y., Shih, T., & Yao, J. C. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2017.0589 · Cited by 3,447
Cancer Disparities by Race/Ethnicity and Socioeconomic Status
Ward, E., Jemal, A., Cokkinides, V., Singh, G. K., Cardinez, C., Ghafoor, A., & Thun, M. (2004) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.54.2.78 · Cited by 1,801
Self-citationThe Effect of Advances in Lung-Cancer Treatment on Population Mortality
Howlader, N., Forjaz, G., Mooradian, M. J., Meza, R., Kong, C. Y., Cronin, K. A., Mariotto, A. B., Lowy, D. R., & Feuer, E. J. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1916623 · Cited by 1,712
Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma
Abou-Alfa, G. K., Lau, G., Kudo, M., Chan, S. L., Kelley, R. K., Furuse, J., Sukeepaisarnjaroen, W., Kang, Y.-K., Van Dao, T., De Toni, E. N., et al. (2022) · NEJM Evidence · doi:10.1056/evidoa2100070 · Cited by 1,576
International Classification of Childhood Cancer, third edition
Steliarova‐Foucher, E., Stiller, C., Lacour, B., & Kaatsch, P. (2005) · Cancer · doi:10.1002/cncr.20910 · Cited by 1,552
Metadata
- Authors
- Siegel, R. L., Kratzer, T. B., Wagle, N. S., Sung, H., & Jemal, A.
- Venue
- CA: A Cancer Journal for Clinicians
- Publisher
- Wiley
- Published
- 2026-01
- Volume
- 76
- Issue
- 1
- Pages
- e70043-e70043
- ISSN
- 0007-9235 (ISSN-L)
- 1542-4863
- OpenAlex
- W7123452202
- Cited by
- 403
- References
- 79
- FWCI
- 1079.96
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Cancer statistics, 2026. https://app.cochat.ai/papers/10.3322/caac.70043
- The paper
- Siegel, R. L., Kratzer, T. B., Wagle, N. S., Sung, H., & Jemal, A. (2026). Cancer statistics, 2026. CA: A Cancer Journal for Clinicians. https://doi.org/10.3322/caac.70043
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.